Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups

• A’Hern Roger,
• DeBono Johann,
• Sandhu Shahneen,
• Kalaitzaki Eletheria,
• Usdin Martine,
• Hall Emma E

Affiliations

A’Hern Roger

DeBono Johann

Sandhu Shahneen

Kalaitzaki Eletheria

Usdin Martine

Hall Emma E